143 related articles for article (PubMed ID: 15138174)
1. Vaccination with recombinant whole heavy chain fragments of Clostridium botulinum Type C and D neurotoxins.
Arimitsu H; Lee JC; Sakaguchi Y; Hayakawa Y; Hayashi M; Nakaura M; Takai H; Lin SN; Mukamoto M; Murphy T; Oguma K
Clin Diagn Lab Immunol; 2004 May; 11(3):496-502. PubMed ID: 15138174
[TBL] [Abstract][Full Text] [Related]
2. C terminal half fragment (50 kDa) of heavy chain components of Clostridium botulinum type C and D neurotoxins can be used as an effective vaccine.
Lee JC; Hwang HJ; Sakaguchi Y; Yamamoto Y; Arimitsu H; Tsuji T; Watanabe T; Ohyama T; Tsuchiya T; Oguma K
Microbiol Immunol; 2007; 51(4):445-55. PubMed ID: 17446685
[TBL] [Abstract][Full Text] [Related]
3. Production and evaluation of a recombinant chimeric vaccine against clostridium botulinum neurotoxin types C and D.
Gil LA; da Cunha CE; Moreira GM; Salvarani FM; Assis RA; Lobato FC; Mendonça M; Dellagostin OA; Conceição FR
PLoS One; 2013; 8(7):e69692. PubMed ID: 23936080
[TBL] [Abstract][Full Text] [Related]
4. Production of serotype C specific and serotype C/D generic monoclonal antibodies using recombinant H(C) and H(N) fragments from Clostridium botulinum neurotoxin types C(1) and D.
Curran RM; Fringuelli E; Graham D; Elliott CT
Vet Immunol Immunopathol; 2009 Jul; 130(1-2):1-10. PubMed ID: 19233482
[TBL] [Abstract][Full Text] [Related]
5. Protective potential of recombinant non-purified botulinum neurotoxin serotypes C and D.
Moreira C; da Cunha CE; Moreira GM; Mendonça M; Salvarani FM; Moreira ÂN; Conceição FR
Anaerobe; 2016 Aug; 40():58-62. PubMed ID: 27236078
[TBL] [Abstract][Full Text] [Related]
6. Protection with recombinant Clostridium botulinum C1 and D binding domain subunit (Hc) vaccines against C and D neurotoxins.
Webb RP; Smith TJ; Wright PM; Montgomery VA; Meagher MM; Smith LA
Vaccine; 2007 May; 25(21):4273-82. PubMed ID: 17395341
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of a potential trivalent vaccine based on Hc fragments of botulinum toxins A, B, and E produced in a cell-free expression system.
Zichel R; Mimran A; Keren A; Barnea A; Steinberger-Levy I; Marcus D; Turgeman A; Reuveny S
Clin Vaccine Immunol; 2010 May; 17(5):784-92. PubMed ID: 20357058
[TBL] [Abstract][Full Text] [Related]
8. Cloning, high level expression and immunogenicity of 1163-1256 residues of C-terminal heavy chain of C. botulinum neurotoxin type E.
Mansour AA; Mousavi SL; Rasooli I; Nazarian S; Amani J; Farhadi N
Biologicals; 2010 Mar; 38(2):260-4. PubMed ID: 19879159
[TBL] [Abstract][Full Text] [Related]
9. Protection with a recombinant Hc of Clostridium Botulinum neurotoxin serotype A from Escherichia coli as an effective subunit vaccine.
Yu YZ; Sun ZW; Li N; Wang S; Wang RL; Yu WY
Immunopharmacol Immunotoxicol; 2009 Jun; 31(2):261-6. PubMed ID: 18932057
[TBL] [Abstract][Full Text] [Related]
10. Cloning, high-level expression, single-step purification, and binding activity of His6-tagged recombinant type B botulinum neurotoxin heavy chain transmembrane and binding domain.
Zhou Y; Singh BR
Protein Expr Purif; 2004 Mar; 34(1):8-16. PubMed ID: 14766296
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Clostridium botulinum types C and D toxoid vaccination in Danish cows.
Krüger M; Skau M; Shehata AA; Schrödl W
Anaerobe; 2013 Oct; 23():97-101. PubMed ID: 23831724
[TBL] [Abstract][Full Text] [Related]
12. Isolation and characterization of a neutralizing antibody specific to internalization domain of Clostridium botulinum neurotoxin type B.
Yang GH; Kim KS; Kim HW; Jeong ST; Huh GH; Kim JC; Jung HH
Toxicon; 2004 Jul; 44(1):19-25. PubMed ID: 15225558
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the D/C mosaic neurotoxin produced by Clostridium botulinum associated with bovine botulism in Japan.
Nakamura K; Kohda T; Umeda K; Yamamoto H; Mukamoto M; Kozaki S
Vet Microbiol; 2010 Jan; 140(1-2):147-54. PubMed ID: 19720474
[TBL] [Abstract][Full Text] [Related]
14. Immune response of horses to vaccination with the recombinant Hc domain of botulinum neurotoxin types C and D.
Stahl C; Unger L; Mazuet C; Popoff M; Straub R; Frey J
Vaccine; 2009 Sep; 27(41):5661-6. PubMed ID: 19646409
[TBL] [Abstract][Full Text] [Related]
15. Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli.
Clayton MA; Clayton JM; Brown DR; Middlebrook JL
Infect Immun; 1995 Jul; 63(7):2738-42. PubMed ID: 7790092
[TBL] [Abstract][Full Text] [Related]
16. Protective efficacy of recombinant bacterin vaccine against botulism in cattle.
Moreira C; Ferreira MRA; Finger PF; Magalhães CG; Cunha CEP; Rodrigues RR; Otaka DY; Galvão CC; Salvarani FM; Moreira ÂN; Conceição FR
Vaccine; 2020 Mar; 38(11):2519-2526. PubMed ID: 32037222
[TBL] [Abstract][Full Text] [Related]
17. Vaccination of cattle with a recombinant bivalent toxoid against botulism serotypes C and D.
Cunha CE; Moreira GM; Salvarani FM; Neves MS; Lobato FC; Dellagostin OA; Conceição FR
Vaccine; 2014 Jan; 32(2):214-6. PubMed ID: 24252701
[TBL] [Abstract][Full Text] [Related]
18. The recombinant Hc subunit of Clostridium botulinum neurotoxin serotype A is an effective botulism vaccine candidate.
Yu YZ; Li N; Zhu HQ; Wang RL; Du Y; Wang S; Yu WY; Sun ZW
Vaccine; 2009 May; 27(21):2816-22. PubMed ID: 19428892
[TBL] [Abstract][Full Text] [Related]
19. Production of recombinant botulism antigens: a review of expression systems.
Moreira GM; Cunha CE; Salvarani FM; Gonçalves LA; Pires PS; Conceição FR; Lobato FC
Anaerobe; 2014 Aug; 28():130-6. PubMed ID: 24930432
[TBL] [Abstract][Full Text] [Related]
20. Protective immunity against botulism provided by a single dose vaccination with an adenovirus-vectored vaccine.
Zeng M; Xu Q; Elias M; Pichichero ME; Simpson LL; Smith LA
Vaccine; 2007 Oct; 25(43):7540-8. PubMed ID: 17897756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
